Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
The estrogen receptor (ER) and/or the human epidermal growth factor receptor 2 (HER2) signaling pathways are the dominant drivers of cell proliferation and survival in the majority of human breast cancers. As a result, targeting these pathways provides the most effective therapies in appropriately s...
Saved in:
| Published in | Breast care (Basel, Switzerland) Vol. 8; no. 4; pp. 256 - 262 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
S. Karger GmbH
01.01.2013
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The estrogen receptor (ER) and/or the human epidermal growth factor receptor 2 (HER2) signaling pathways are the dominant drivers of cell proliferation and survival in the majority of human breast cancers. As a result, targeting these pathways provides the most effective therapies in appropriately selected patients. Nevertheless, resistance to both endocrine and anti-HER2 therapies occurs frequently and represents a major clinical challenge. Compelling preclinical and clinical evidence relates this treatment resistance to the presence of a complex bidirectional molecular crosstalk between the ER and HER2 pathways. As a consequence, treatment strategies targeting either pathway are associated with up-regulation of the other one, ultimately resulting in resistance to therapy. Therefore, a more promising strategy to prevent or overcome either endocrine or anti-HER2 resistance at least in some tumors is to combine targeted treatments that simultaneously block both signaling pathways. Many clinical trials exploring this strategy have shown positive results, and many more are currently ongoing. Future clinical trials with appropriate patient selection, based on biomarker evaluation of primary tumors and possibly of recurrent lesions, are warranted for the optimization of individualized therapeutic strategies. |
|---|---|
| AbstractList | The estrogen receptor (ER) and/or the human epidermal growth factor receptor 2 (HER2) signaling pathways are the dominant drivers of cell proliferation and survival in the majority of human breast cancers. As a result, targeting these pathways provides the most effective therapies in appropriately selected patients. Nevertheless, resistance to both endocrine and anti-HER2 therapies occurs frequently and represents a major clinical challenge. Compelling preclinical and clinical evidence relates this treatment resistance to the presence of a complex bidirectional molecular crosstalk between the ER and HER2 pathways. As a consequence, treatment strategies targeting either pathway are associated with up-regulation of the other one, ultimately resulting in resistance to therapy. Therefore, a more promising strategy to prevent or overcome either endocrine or anti-HER2 resistance at least in some tumors is to combine targeted treatments that simultaneously block both signaling pathways. Many clinical trials exploring this strategy have shown positive results, and many more are currently ongoing. Future clinical trials with appropriate patient selection, based on biomarker evaluation of primary tumors and possibly of recurrent lesions, are warranted for the optimization of individualized therapeutic strategies. |
| Author | Schiff, Rachel Giuliano, Mario Trivedi, Meghana V. |
| AuthorAffiliation | e Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA b Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy, Houston, TX, USA d Margaret M. and Albert B. Alkek Department of Medicine, Baylor College of Medicine, Houston, TX, USA c Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA a Lester and Sue Smith Breast Center, Baylor College of Medicine, University of Houston, College of Pharmacy, Houston, TX, USA |
| AuthorAffiliation_xml | – name: c Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA – name: a Lester and Sue Smith Breast Center, Baylor College of Medicine, University of Houston, College of Pharmacy, Houston, TX, USA – name: b Department of Clinical Sciences and Administration, University of Houston, College of Pharmacy, Houston, TX, USA – name: d Margaret M. and Albert B. Alkek Department of Medicine, Baylor College of Medicine, Houston, TX, USA – name: e Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA |
| Author_xml | – sequence: 1 givenname: Mario surname: Giuliano fullname: Giuliano, Mario – sequence: 2 givenname: Meghana V. surname: Trivedi fullname: Trivedi, Meghana V. – sequence: 3 givenname: Rachel surname: Schiff fullname: Schiff, Rachel |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24415978$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkU1v1DAQhiNURD_gwB0hS1zKYcGO8-H0gMRG2w-pCFTgHE2ccdY0sYPt7ao_i3-Il20jkDh5rHned0bzHicHxhpMkpeMvmMsr95TSnmepTl_khyxomALLmh-8FiXFTtMjr3_QWlW8LJ4lhymWRZ1pThKfi11px3KoK2BgdTOeh9guCUthi2iIWGNZOWDs3383KDEKVhHwHTkcjOCIatJd-jGqL1wdhvW5BzkjpjRlHzVffTWpidfIKy3cO-JNmTpEHwgNRiJ7ox8sgPKzQCOLMFr_2dCHUVaRuurcRpisVvSP0-eKhg8vnh4T5Lv56tv9eXi-vPFVf3xeiGzioaFyrOuUF2HSlUlLznItMIuA8FKJahqObRZLlQqeUHzgpZVVQgUVdpyShFB8ZPkw9532rQjdhJNcDA0k9MjuPvGgm7-7Ri9bnp718Tji5Rl0eD0wcDZnxv0oRm1lzgMYNBufMPyjDIqKiEi-naPyt39Hap5DKPNLuJmjjiyr__eayYfM43Aqz1wC65HNwOz_s1_28ubek80U6f4b3PFvDU |
| CitedBy_id | crossref_primary_10_1016_j_jsbmb_2018_04_007 crossref_primary_10_1177_1060028018824088 crossref_primary_10_1186_s13058_020_01325_3 crossref_primary_10_2174_1568009621666210216102236 crossref_primary_10_1111_rssc_12536 crossref_primary_10_1016_j_ctrv_2023_102529 crossref_primary_10_1016_j_ejmech_2024_116393 crossref_primary_10_1007_s10549_018_4966_9 crossref_primary_10_1007_s13273_019_00053_w crossref_primary_10_1093_annonc_mdz055 crossref_primary_10_1007_s00280_022_04478_4 crossref_primary_10_1002_1878_0261_13141 crossref_primary_10_3390_cancers15010126 crossref_primary_10_1186_s12885_022_10163_9 crossref_primary_10_20960_revcancer_00019 crossref_primary_10_58600_eurjther2151 crossref_primary_10_3390_cancers14102380 crossref_primary_10_1016_j_biopha_2024_116615 crossref_primary_10_1016_j_breast_2015_07_015 crossref_primary_10_1007_s40261_018_0741_2 crossref_primary_10_1080_02664763_2024_2362275 crossref_primary_10_1016_j_cpme_2020_100109 crossref_primary_10_1016_j_ejca_2019_06_001 crossref_primary_10_1186_s13058_018_1072_1 crossref_primary_10_1016_j_clbc_2021_03_005 crossref_primary_10_1016_j_ctarc_2021_100483 crossref_primary_10_3389_fonc_2021_774088 crossref_primary_10_1210_endrev_bnac017 crossref_primary_10_3390_ijms21103711 crossref_primary_10_1016_j_sajb_2023_12_002 crossref_primary_10_18632_oncotarget_13213 crossref_primary_10_1371_journal_pone_0167397 crossref_primary_10_3389_fonc_2022_975463 crossref_primary_10_1038_s41523_023_00572_9 crossref_primary_10_1016_j_bcp_2022_115209 crossref_primary_10_1016_j_ctrv_2022_102500 crossref_primary_10_1016_j_bbrep_2022_101326 crossref_primary_10_1002_cncr_29060 crossref_primary_10_1007_s10549_024_07291_0 crossref_primary_10_1186_s12957_024_03365_x crossref_primary_10_1139_er_2016_0075 crossref_primary_10_1080_1120009X_2021_2009722 crossref_primary_10_3389_fonc_2018_00089 crossref_primary_10_1111_his_14331 crossref_primary_10_1002_jso_24762 crossref_primary_10_1007_s00280_016_3211_7 crossref_primary_10_1007_s10549_022_06698_x crossref_primary_10_1016_j_breast_2020_10_014 crossref_primary_10_1002_cncr_35174 crossref_primary_10_1038_s41588_018_0287_5 crossref_primary_10_1001_jamanetworkopen_2021_33132 crossref_primary_10_1007_s10549_022_06832_9 crossref_primary_10_3389_fgene_2020_00349 crossref_primary_10_1016_j_breast_2016_07_026 crossref_primary_10_1016_j_ijrobp_2020_01_031 crossref_primary_10_3390_cells11233850 crossref_primary_10_1177_17588359231220501 crossref_primary_10_1093_carcin_bgy182 crossref_primary_10_1158_1078_0432_CCR_21_1584 crossref_primary_10_1016_j_taap_2024_116804 crossref_primary_10_1038_s41523_023_00533_2 crossref_primary_10_1007_s10549_020_05942_6 crossref_primary_10_1016_j_ctrv_2018_08_004 crossref_primary_10_1186_s12885_024_11871_0 crossref_primary_10_18632_oncotarget_27789 crossref_primary_10_1016_j_neo_2015_11_002 crossref_primary_10_12677_ACM_2023_1381800 crossref_primary_10_37349_etat_2022_00081 crossref_primary_10_1186_s13058_022_01598_w crossref_primary_10_1186_s12964_023_01441_5 crossref_primary_10_5507_bp_2019_060 crossref_primary_10_18632_oncotarget_18431 crossref_primary_10_1007_s10911_014_9329_5 crossref_primary_10_3390_jcm13071873 crossref_primary_10_18632_oncotarget_4441 crossref_primary_10_1001_jamaoncol_2022_4175 crossref_primary_10_2217_fon_2022_0045 crossref_primary_10_1158_1078_0432_CCR_19_2612 crossref_primary_10_1186_s12885_019_5301_5 crossref_primary_10_3390_cancers14163996 crossref_primary_10_1200_JCO_20_00147 crossref_primary_10_1371_journal_pone_0216469 crossref_primary_10_3390_ijms25116259 crossref_primary_10_1158_1078_0432_CCR_18_1114 crossref_primary_10_2217_fon_2015_0025 crossref_primary_10_1186_s12885_024_12179_9 crossref_primary_10_1177_15330338211065603 crossref_primary_10_3390_cancers14225650 crossref_primary_10_1158_1078_0432_CCR_23_0117 crossref_primary_10_1016_j_breast_2023_06_006 crossref_primary_10_1016_j_genrep_2020_101007 crossref_primary_10_1007_s10549_019_05505_4 crossref_primary_10_1016_j_jsbmb_2016_03_019 crossref_primary_10_1158_1541_7786_MCR_15_0423 crossref_primary_10_1177_1758834014535650 crossref_primary_10_3390_cancers12113317 crossref_primary_10_1002_rmb2_12006 crossref_primary_10_1016_j_jsbmb_2021_105961 crossref_primary_10_3390_cancers14204981 crossref_primary_10_3390_cancers14143305 crossref_primary_10_1038_s41416_023_02426_4 crossref_primary_10_1007_s10147_024_02528_w crossref_primary_10_1016_j_nano_2020_102197 crossref_primary_10_2147_BCTT_S457845 crossref_primary_10_3390_cancers15174374 crossref_primary_10_1161_CIRCHEARTFAILURE_121_008997 |
| Cites_doi | 10.1038/nrm1962 10.2119/molmed.2012.00302 10.1002/jcb.10409 10.1158/1078-0432.CCR-10-2920 10.1158/0008-5472.CAN-05-4363 10.1016/S0959-8049(05)80215-1 10.1093/jnci/95.2.142 10.1677/jme.0.0240329 10.1038/sj.bjc.6605324 10.1016/S0960-0760(00)00108-4 10.1186/bcr2594 10.1016/S0140-6736(11)61351-2 10.1200/JCO.2009.23.3734 10.1158/0008-5472.CAN-09-0042 10.1210/er.20.3.321 10.1016/S0140-6736(04)16981-X 10.1517/14712598.2013.783007 10.1002/ijc.1614 10.1158/0008-5472.CAN-07-0702 10.1200/JCO.2012.44.8027 10.1007/s10549-012-2067-8 10.1093/jnci/djh166 10.1677/erc.1.00776 10.1186/bcr3067 10.1016/j.steroids.2008.10.014 10.1172/JCI34739 10.1073/pnas.0602468103 10.1002/jcb.1142 10.1146/annurev-med-070909-182917 10.1038/sj.onc.1203416 10.1002/14651858.CD004562.pub4 10.1196/annals.1339.026 10.1158/1078-0432.CCR-10-1869 10.1074/jbc.M010840200 10.1128/MCB.24.19.8681-8690.2004 10.1200/JCO.2008.20.6847 10.1056/NEJMoa1109653 10.1038/35021093 10.1073/pnas.191367098 10.1126/science.270.5241.1491 10.1158/1078-0432.CCR-09-2282 10.1200/JCO.2005.12.157 10.1073/pnas.1219992110 10.1210/er.2006-0045 10.1038/onc.2012.261 10.1101/gad.1944810 |
| ContentType | Journal Article |
| Copyright | 2013 S. Karger GmbH, Freiburg Copyright © 2013 by S. Karger GmbH, Freiburg 2013 |
| Copyright_xml | – notice: 2013 S. Karger GmbH, Freiburg – notice: Copyright © 2013 by S. Karger GmbH, Freiburg 2013 |
| DBID | NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1159/000354253 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1661-3805 |
| EndPage | 262 |
| ExternalDocumentID | 10_1159_000354253 24415978 354253 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P50 CA058183 – fundername: NCI NIH HHS grantid: P30 CA125123 |
| GroupedDBID | --- 0R~ 0~5 0~B 23N 36B 3O. 4.4 53G 5GY 6PF 8UI AAKDD AAWTL AAYIC ABJNI ABPAZ ACGFS ACPSR ADBBV AENEX AEYAO AFJJK ALDHI ALMA_UNASSIGNED_HOLDINGS AZPMC CAG COF CS3 CYUIP DU5 E0A EBS EIHBH EJD F5P FB. HYE HZ~ IY7 KUZGX N9A O1H O9- OK1 P2P RKO RPM UJ6 VUG WQ9 NPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c490t-f54d6fddeff97373ac29ed4a817f80fb3ab458f2c36056079968e892b300eeaf3 |
| IEDL.DBID | RPM |
| ISSN | 1661-3791 |
| IngestDate | Tue Sep 17 21:27:34 EDT 2024 Fri Aug 16 09:06:08 EDT 2024 Fri Dec 06 06:09:53 EST 2024 Sat Sep 28 07:57:44 EDT 2024 Thu Sep 05 19:48:46 EDT 2024 Thu Aug 29 12:04:30 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Resistance HER2 Estrogen Receptor Crosstalk |
| Language | English |
| License | Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. https://www.karger.com/Services/SiteLicenses |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c490t-f54d6fddeff97373ac29ed4a817f80fb3ab458f2c36056079968e892b300eeaf3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://www.karger.com/Article/Pdf/354253 |
| PMID | 24415978 |
| PQID | 1540108988 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3808214 crossref_primary_10_1159_000354253 pubmed_primary_24415978 karger_primary_354253 proquest_miscellaneous_1540108988 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-01-01 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – month: 01 year: 2013 text: 2013-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Wilhelmstrasse 20A, P.O. Box · Postfach · Case postale, D–79095, Freiburg, Germany · Deutschland · Allemagne, Phone: +49 761 45 20 70, Fax: +49 761 4 52 07 14, information@karger.de |
| PublicationTitle | Breast care (Basel, Switzerland) |
| PublicationTitleAlternate | Breast Care |
| PublicationYear | 2013 |
| Publisher | S. Karger GmbH |
| Publisher_xml | – name: S. Karger GmbH |
| References | Nahta R, O'Regan RM: Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 2012;135:39-48.2252711210.1007/s10549-012-2067-8 Goel S, Sharma R, Hamilton A, Beith J: LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009;(4):CD004562.1982132810.1002/14651858.CD004562.pub4 Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993;29A:1018-1023.809894610.1016/S0959-8049(05)80215-1 Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.1978665810.1200/JCO.2009.23.3734 Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153.1252934710.1093/jnci/95.2.142 Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS, Rhodes DR, Liu XS, Brown M: Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010;24:2219-2227.2088971810.1101/gad.1944810 Fox EM, Andrade J, Shupnik MA: Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 2009;74:622-627.1899613610.1016/j.steroids.2008.10.014 Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III tandem study. J Clin Oncol 2009;27:5529-5537.1978667010.1200/JCO.2008.20.6847 Guo S, Sonenshein GE: Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the HER-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2004;24:8681-8690.1536768610.1128/MCB.24.19.8681-8690.2004 Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000;74:311-317.1116293910.1016/S0960-0760(00)00108-4 Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M: Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: A randomized phase II study. Clin Cancer Res 2011;17:1147-1159.2122048010.1158/1078-0432.CCR-10-1869 Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/Akt-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-9824.1113958810.1074/jbc.M010840200 Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D: Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006;66:3903-3911.1658521910.1158/0008-5472.CAN-05-4363 Lee AV, Cui X, Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001;7:4429s-4435s; discussion 4411s-4412s.11916236 Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.1155381510.1073/pnas.191367098 Yarden RI, Wilson MA, Chrysogelos SA: Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl 2001;36(suppl):232-246.1145558810.1002/jcb.1142 Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R: Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 2010;12:R40.2056950310.1186/bcr2594 Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH: Resistance to tamoxifen-induced apoptosis is associated with direct interaction between HER2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002;97:306-312.1177428110.1002/ijc.1614 Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Perez-Soler R, Horwitz SB, McDaid HM: Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007;67:11300-11308.1805645610.1158/0008-5472.CAN-07-0702 Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-1484.2192448610.1016/S0140-6736(11)61351-2 Vyhlidal C, Samudio I, Kladde MP, Safe S: Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J Mol Endocrinol 2000;24:329-338.1082882610.1677/jme.0.0240329 Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL: A model of acquired autoresistance to a potent erbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 2006;103:7795-7800.1668262210.1073/pnas.0602468103 Nemere I, Pietras RJ, Blackmore PF: Membrane receptors for steroid hormones: signal transduction and physiological significance. J Cell Biochem 2003;88:438-445.1253232010.1002/jcb.10409 Osborne CK, Schiff R, Fuqua SA, Shou J: Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001;7:4338s-4342s; discussion 4411s-4412s.11916222 McKenna NJ, Lanz RB, O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-344.1036877410.1210/er.20.3.321 Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, Lanari C, Helguero LA: Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 2013;32:2390-2402.2275111010.1038/onc.2012.261 Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447S-454S.12538499 Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC: Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-over-expressing breast cancer: TBCRC 006. J Clin Oncol 2013;31:1726-1731.2356931510.1200/JCO.2012.44.8027 Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL: Loss of phosphatase and tensin homologue deleted on chromosome 10 engages erbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009;69:4192-4201.1943589310.1158/0008-5472.CAN-09-0042 Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S: Study of the biologic effects of lapatinib, a reversible inhibitor of erbB1 and erbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-2512.1568431110.1200/JCO.2005.12.157 Arpino G, Wiechmann L, Osborne CK, Schiff R: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-233.1821621910.1210/er.2006-0045 Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-2183.8641283 Flageng MH, Moi LL, Dixon JM, Geisler J, Lien EA, Miller WR, Lonning PE, Mellgren G: Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 2009;101:1253-1260.1975598410.1038/sj.bjc.6605324 Magnani L, Stoeck A, Zhang X, Lanczky A, Mirabella AC, Wang TL, Gyorffy B, Lupien M: Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA 2013;110:E1490-E1499.2357673510.1073/pnas.1219992110 Lan KH, Lu CH, Yu D: Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 2005;1059:70-75.1638204510.1196/annals.1339.026 Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC: Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of erbB2 expression in breast cancer. Oncoge 16682622 - Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800 7491495 - Science. 1995 Dec 1;270(5241):1491-4 21924486 - Lancet. 2011 Oct 22;378(9801):1461-84 19435893 - Cancer Res. 2009 May 15;69(10 ):4192-201 23530718 - Expert Opin Biol Ther. 2013 May;13(5):779-90 10698518 - Oncogene. 2000 Jan 27;19(4):490-7 20215537 - Clin Cancer Res. 2010 Mar 15;16(6):1904-14 19821328 - Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004562 11139588 - J Biol Chem. 2001 Mar 30;276(13):9817-24 11916222 - Clin Cancer Res. 2001 Dec;7(12 Suppl):4338s-4342s; discussion 4411s-4412s 19755984 - Br J Cancer. 2009 Oct 20;101(8):1253-60 23576735 - Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1490-9 12532320 - J Cell Biochem. 2003 Feb 15;88(3):438-45 18725988 - J Clin Invest. 2008 Sep;118(9):3065-74 10828826 - J Mol Endocrinol. 2000 Jun;24(3):329-38 11162939 - J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):311-7 8098946 - Eur J Cancer. 1993;29A(7):1018-23 21220480 - Clin Cancer Res. 2011 Mar 1;17(5):1147-59 20569503 - Breast Cancer Res. 2010;12(3):R40 20889718 - Genes Dev. 2010 Oct 1;24(19):2219-27 15684311 - J Clin Oncol. 2005 Apr 10;23(11):2502-12 16585219 - Cancer Res. 2006 Apr 1;66(7):3903-11 15613444 - Endocr Relat Cancer. 2004 Dec;11(4):643-58 23196784 - Mol Med. 2013 Jan 22;18:1473-9 19786670 - J Clin Oncol. 2009 Nov 20;27(33):5529-37 11916236 - Clin Cancer Res. 2001 Dec;7(12 Suppl):4429s-4435s; discussion 4411s-4412s 16382045 - Ann N Y Acad Sci. 2005 Nov;1059:70-5 20887199 - Annu Rev Med. 2011;62:233-47 10368774 - Endocr Rev. 1999 Jun;20(3):321-44 22123186 - Breast Cancer Res. 2011;13(6):R121 12538499 - Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S 18056456 - Cancer Res. 2007 Dec 1;67(23 ):11300-8 21415222 - Clin Cancer Res. 2011 Jul 1;17(13):4208-13 22149876 - N Engl J Med. 2012 Feb 9;366(6):520-9 18216219 - Endocr Rev. 2008 Apr;29(2):217-33 23569315 - J Clin Oncol. 2013 May 10;31(14):1726-31 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 18996136 - Steroids. 2009 Jul;74(7):622-7 19786658 - J Clin Oncol. 2009 Nov 20;27(33):5538-46 15367686 - Mol Cell Biol. 2004 Oct;24(19):8681-90 11455588 - J Cell Biochem Suppl. 2001;Suppl 36:232-46 11774281 - Int J Cancer. 2002 Jan 20;97(3):306-12 22527112 - Breast Cancer Res Treat. 2012 Aug;135(1):39-48 15351193 - Lancet. 2004 Sep 4-10;364(9437):858-68 12529347 - J Natl Cancer Inst. 2003 Jan 15;95(2):142-53 16829981 - Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 15199112 - J Natl Cancer Inst. 2004 Jun 16;96(12):926-35 12514567 - Cancer Control. 2002 Nov-Dec;9(6):490-8 10963602 - Nature. 2000 Aug 17;406(6797):747-52 8641283 - EMBO J. 1996 May 1;15(9):2174-83 22751110 - Oncogene. 2013 May 9;32(19):2390-402 ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref39 ref16 ref38 ref19 ref18 ref24 ref46 ref23 ref45 ref26 ref25 ref20 ref42 ref41 ref22 ref44 ref21 ref43 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 |
| References_xml | – ident: ref16 doi: 10.1038/nrm1962 – ident: ref20 doi: 10.2119/molmed.2012.00302 – ident: ref7 doi: 10.1002/jcb.10409 – ident: ref10 doi: 10.1158/1078-0432.CCR-10-2920 – ident: ref28 doi: 10.1158/0008-5472.CAN-05-4363 – ident: ref15 doi: 10.1016/S0959-8049(05)80215-1 – ident: ref26 doi: 10.1093/jnci/95.2.142 – ident: ref35 doi: 10.1677/jme.0.0240329 – ident: ref38 doi: 10.1038/sj.bjc.6605324 – ident: ref6 doi: 10.1016/S0960-0760(00)00108-4 – ident: ref33 doi: 10.1186/bcr2594 – ident: ref1 doi: 10.1016/S0140-6736(11)61351-2 – ident: ref40 doi: 10.1200/JCO.2009.23.3734 – ident: ref24 doi: 10.1158/0008-5472.CAN-09-0042 – ident: ref5 doi: 10.1210/er.20.3.321 – ident: ref11 doi: 10.1016/S0140-6736(04)16981-X – ident: ref19 doi: 10.1517/14712598.2013.783007 – ident: ref14 doi: 10.1002/ijc.1614 – ident: ref45 doi: 10.1158/0008-5472.CAN-07-0702 – ident: ref41 doi: 10.1200/JCO.2012.44.8027 – ident: ref23 doi: 10.1007/s10549-012-2067-8 – ident: ref13 doi: 10.1093/jnci/djh166 – ident: ref9 doi: 10.1677/erc.1.00776 – ident: ref21 doi: 10.1186/bcr3067 – ident: ref34 doi: 10.1016/j.steroids.2008.10.014 – ident: ref46 doi: 10.1172/JCI34739 – ident: ref22 doi: 10.1073/pnas.0602468103 – ident: ref36 doi: 10.1002/jcb.1142 – ident: ref12 doi: 10.1146/annurev-med-070909-182917 – ident: ref37 doi: 10.1038/sj.onc.1203416 – ident: ref8 doi: 10.1002/14651858.CD004562.pub4 – ident: ref17 doi: 10.1196/annals.1339.026 – ident: ref42 doi: 10.1158/1078-0432.CCR-10-1869 – ident: ref25 doi: 10.1074/jbc.M010840200 – ident: ref27 doi: 10.1128/MCB.24.19.8681-8690.2004 – ident: ref39 doi: 10.1200/JCO.2008.20.6847 – ident: ref44 doi: 10.1056/NEJMoa1109653 – ident: ref2 doi: 10.1038/35021093 – ident: ref3 doi: 10.1073/pnas.191367098 – ident: ref30 doi: 10.1126/science.270.5241.1491 – ident: ref43 doi: 10.1158/1078-0432.CCR-09-2282 – ident: ref18 doi: 10.1200/JCO.2005.12.157 – ident: ref32 doi: 10.1073/pnas.1219992110 – ident: ref4 doi: 10.1210/er.2006-0045 – ident: ref29 doi: 10.1038/onc.2012.261 – ident: ref31 doi: 10.1101/gad.1944810 |
| SSID | ssj0046376 |
| Score | 2.351325 |
| SecondaryResourceType | review_article |
| Snippet | The estrogen receptor (ER) and/or the human epidermal growth factor receptor 2 (HER2) signaling pathways are the dominant drivers of cell proliferation and... |
| SourceID | pubmedcentral proquest crossref pubmed karger |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 256 |
| SubjectTerms | Review Article · Übersichtsarbeit Review · Übersichtsarbeit |
| Title | Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications |
| URI | https://karger.com/doi/10.1159/000354253 https://www.ncbi.nlm.nih.gov/pubmed/24415978 https://search.proquest.com/docview/1540108988 https://pubmed.ncbi.nlm.nih.gov/PMC3808214 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELXaCiEuiI8CgYIGxDXdJHYSmxsb7VKQFlVApd4iO7bbqNvsapMK8bP4h4ydZNlWnLjajh1pxp73xuMZQt5nLDJaKRtykyYhs0LhltLIUjIpNdcsFZV7jbz4mp2csS_n6fkeSce3MD5ov1L1cbO8Pm7qSx9bub6uJmOc2OR0UVCOhitmk32yj-Z3pOj98csy6ivKxZlzrOQiHtIJodme-HszVFJXPCdxRMJXV9uxR_euXPj15l9o827Q5I4Vmj8iDwf4CB_733xM9kzzhNxfDBfkT8nvad0bKe_hg8KtifD6CoZ4LEC8B7O226xQcQAxo1kj6QbZaPDufJi5irF4WC_hExL07hLmviDP36EJfK8vHHpvLuAU4eNP-auFuoGpi27voHBatPkAi7HsLkxlW7d-hSEH6RI-74SxH5Kz-exHcRIOVRnCiomoC23KdGbxVLRW5DSnskqE0UzyOLc8sopKxVJuk4oiU8qiHAkVN1wkikaRMdLSZ-SgWTXmBQGeV0oyY1NVaWZ0royIcSxOqmhqrAzIu1E25bpPvlF60pKKcivLgBz2UtsOGduP7rRPvxV9V7nWNiBvRxmXuKPcNYlszOqmLRFUIknlgvOAPO9lvp1i1JqA5Le0YTvAZeu-3YNK7LN2D0r78r-_fEUeJL4Wh_P_HJGDbnNjXiMi6tQbvwP-APrQDv4 |
| link.rule.ids | 230,314,727,780,784,885,27924,27925,53791,53793 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKQdAL4qNAoIBBXNNNYiexubHRLltoqgpaqbfIju026ja72qSq-Fn8Q8ZOsmwrTlxtx440Y8974_EMQp8SGmglpfGZjiOfGi5hSylgKYkQiika89K-Rs6Pktkp_XYWn22heHgL44L2S1nt1_Or_bq6cLGVy6tyNMSJjY7zjDAwXCEd3UP3Y5LycCDp3QFME-JqyoWJda1Ad59QCAz3yN2cgZra8jmRpRKuvtqGRXpwaQOwV__Cm3fDJjfs0PQJetwDSPyl-9GnaEvXz9DDvL8if45-j6vOTDkfH87smgCwL3EfkYUB8eFJ064WoDoYUKNeAu3GolbYOfTxxNaMheN6jr8CRW8v8NSV5Pk7NMI_q3OL3-tzfAwA8kb8anBV47GNb29xZvVo9RnnQ-FdPBZN1bgV-iykc3ywEci-i06nk5Ns5vd1GfyS8qD1TUxVYuBcNIanJCWijLhWVLAwNSwwkghJY2aikgBXSoIUKBXTjEeSBIHWwpAXaLte1PoVwiwtpaDaxLJUVKtUah7CWJhUklgb4aGPg2yKZZd-o3C0JebFWpYe2u2kth4ytO_daR__yLquYqmMhz4MMi5gT9mLElHrxXVTAKwEmso4Yx562cl8PcWgNR5Kb2nDeoDN1327B9TY5e3u1fb1f3_5Hj2aneSHxeHB0fc3aCdylTmsN2gPbbera_0W8FEr37nd8AdY9BJT |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgoIkXxMeAwIAL4jVrEjuJwxsNLRvQqQIm7S2yY3uL1qVVkwnxs_iHXDtJ6SaeeE3cpNI99j3HvrmHkHcJC7SS0vhcx5HPTCZxSilUKYkQiisWZ6X9Gnl2nByesM-n8emW1Zcr2i9ldVAvLg_q6tzVVq4uy9FQJzaaz3LKMXGFbLRSZnSb3IkpgmwQ6t0izBLqfOXCxG6vpFnYNxXC5D1yp2cIVWuhE1k54TzWtrLS3QtbhL3-F-e8WTq5lYumD8j9nkTCh-7PPiS3dP2I7M76Y_LH5Pe46lKV2-eD3L4TSfYF9FVZgKwPJk27XiJ8AJmjXqH0BlErcJv6MLG-sbhkL-ATyvT2HKbOlufv0Ai-V2eWw9dnMEcS-VP8aqCqYWxr3FvILZbW72E2mO_CWDRV497QdyJdwNFWMfseOZlOfuSHfu_N4JcsC1rfxEwlBtdGY7KUplSUUaYVEzxMDQ-MpEKymJuopKiXkiBFWcU1zyJJg0BrYegTslMva_2MAE9LKZg2sSwV0yqVOgtxLD5U0lgb4ZG3Q2yKVdeCo3DSJc6KTSw9stdFbTNkuL5_4_r4W97dKhA-HnkzxLjAeWUPS0Stl1dNgdQSpSrPOPfI0y7mm0cMqPFIeg0NmwG2Z_f1Owhl17u7h-7z__7la7I7_zgtvh4df3lB7kXOnMNuCO2TnXZ9pV8iRWrlKzcZ_gA20hNm |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bidirectional+Crosstalk+between+the+Estrogen+Receptor+and+Human+Epidermal+Growth+Factor+Receptor+2+Signaling+Pathways+in+Breast+Cancer%3A+Molecular+Basis+and+Clinical+Implications&rft.jtitle=Breast+care+%28Basel%2C+Switzerland%29&rft.au=Giuliano%2C+Mario&rft.au=Trivedi%2C+Meghana+V&rft.au=Schiff%2C+Rachel&rft.date=2013-01-01&rft.issn=1661-3791&rft.volume=8&rft.issue=4&rft.spage=256&rft.epage=262&rft_id=info:doi/10.1159%2F000354253&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1661-3791&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1661-3791&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1661-3791&client=summon |